References: 1. Puig S, Berrocal A. Management of high-risk and advanced basaI cell carcinoma. Clin Transl Oncol. 2015;17(7):497-503. 2. Cameron MC, Lee E, Hibler BP, et aI. Basal cell carcinoma: epidemiology; pathophysiology; cIinicaI and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303-317. 3. Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev. 2018;64:1-10. 4. Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal celI carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151(9):976-981. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Basal Cell Skin Cancer V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March 1, 2021. To view the most recent and complete version of the guidelines, go onIine to NCCN.org. 6. Erivedge [package insert]. South San Francisco, CA: Genentech, Inc.; 2020. 7. Odomzo [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2019. 8. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(332):1-10. 9. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(2):372-381. 10. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716-728.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.